File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: A randomised double-blind, placebo-controlled crossover study

TitleThe efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: A randomised double-blind, placebo-controlled crossover study
Authors
KeywordsHealth-related quality of life
Oral health
Salivary flow rate
Sjögren's syndrome
Issue Date2008
PublisherSpringer-Verlag London Ltd. The Journal's web site is located at http://link.springer.de/link/service/journals/10067/
Citation
Clinical Rheumatology, 2008, v. 27 n. 4, p. 429-436 How to Cite?
AbstractCevimeline hydrochloride, a specific agonist of the M3 muscarinic receptor, is beneficial in the treatment of symptoms of xerostomia and xerophthalmia associated with Sjögren's syndrome (SS). Cevimeline has not been evaluated in southern Chinese patients. Furthermore, the effects of cevimeline on health-related quality of life and oral health status are not known. In this randomised, double-blind, placebo-controlled crossover study, patients received cevimeline 30 mg or matched placebo three times per day over 10 weeks followed by a 4-week washout period before treatment crossover. Participants self-completed the following questionnaires: Xerostomia Inventory (XI), the General Oral Health Assessment Index (GOHAI), the Ocular Surface Disease Index (OSDI) and the Medical Outcomes Short Form (SF-36). Clinical assessments included sialometry, examination of the oral cavity for the degree of xerostomia and dental complications of xerostomia. Fifty patients (22 primary SS and 28 secondary SS) were enrolled in the trial. Forty-four patients completed the study. There was a significant improvement in the XI and GOHAI scores as well as the objective rating of xerostomic signs of the oral cavity after treatment with cevimeline. However, there was no improvement in salivary flow rates and dry eye symptoms. SS patients had lower SF-36 scores, but these did not improve after treatment with cevimeline. © Clinical Rheumatology 2007.
Persistent Identifierhttp://hdl.handle.net/10722/91670
ISSN
2014 Impact Factor: 1.696
2014 SCImago Journal Rankings: 0.588
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, KCMen_HK
dc.contributor.authorMcMillan, ASen_HK
dc.contributor.authorWong, MCMen_HK
dc.contributor.authorLeung, WKen_HK
dc.contributor.authorMok, MYen_HK
dc.contributor.authorLau, CSen_HK
dc.date.accessioned2010-09-17T10:23:05Z-
dc.date.available2010-09-17T10:23:05Z-
dc.date.issued2008en_HK
dc.identifier.citationClinical Rheumatology, 2008, v. 27 n. 4, p. 429-436en_HK
dc.identifier.issn0770-3198en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91670-
dc.description.abstractCevimeline hydrochloride, a specific agonist of the M3 muscarinic receptor, is beneficial in the treatment of symptoms of xerostomia and xerophthalmia associated with Sjögren's syndrome (SS). Cevimeline has not been evaluated in southern Chinese patients. Furthermore, the effects of cevimeline on health-related quality of life and oral health status are not known. In this randomised, double-blind, placebo-controlled crossover study, patients received cevimeline 30 mg or matched placebo three times per day over 10 weeks followed by a 4-week washout period before treatment crossover. Participants self-completed the following questionnaires: Xerostomia Inventory (XI), the General Oral Health Assessment Index (GOHAI), the Ocular Surface Disease Index (OSDI) and the Medical Outcomes Short Form (SF-36). Clinical assessments included sialometry, examination of the oral cavity for the degree of xerostomia and dental complications of xerostomia. Fifty patients (22 primary SS and 28 secondary SS) were enrolled in the trial. Forty-four patients completed the study. There was a significant improvement in the XI and GOHAI scores as well as the objective rating of xerostomic signs of the oral cavity after treatment with cevimeline. However, there was no improvement in salivary flow rates and dry eye symptoms. SS patients had lower SF-36 scores, but these did not improve after treatment with cevimeline. © Clinical Rheumatology 2007.en_HK
dc.languageengen_HK
dc.publisherSpringer-Verlag London Ltd. The Journal's web site is located at http://link.springer.de/link/service/journals/10067/en_HK
dc.relation.ispartofClinical Rheumatologyen_HK
dc.subjectHealth-related quality of lifeen_HK
dc.subjectOral healthen_HK
dc.subjectSalivary flow rateen_HK
dc.subjectSjögren's syndromeen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshChinaen_HK
dc.subject.meshCross-Over Studiesen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshHealth Surveysen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMuscarinic Agonists - adverse effects - therapeutic useen_HK
dc.subject.meshOral Healthen_HK
dc.subject.meshPatient Satisfactionen_HK
dc.subject.meshQuality of Lifeen_HK
dc.subject.meshQuinuclidines - adverse effects - therapeutic useen_HK
dc.subject.meshSeverity of Illness Indexen_HK
dc.subject.meshSjogren's Syndrome - complications - ethnologyen_HK
dc.subject.meshThiophenes - adverse effects - therapeutic useen_HK
dc.subject.meshXerostomia - drug therapy - ethnology - etiologyen_HK
dc.titleThe efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: A randomised double-blind, placebo-controlled crossover studyen_HK
dc.typeArticleen_HK
dc.identifier.emailLeung, KCM: kcmleung@hkucc.hku.hken_HK
dc.identifier.emailMcMillan, AS: annemcmillan@hku.hken_HK
dc.identifier.emailWong, MCM: mcmwong@hkucc.hku.hken_HK
dc.identifier.emailLeung, WK: ewkleung@hkucc.hku.hken_HK
dc.identifier.emailMok, MY: temy@hkucc.hku.hken_HK
dc.identifier.emailLau, CS: cslau@hku.hken_HK
dc.identifier.authorityLeung, KCM=rp00032en_HK
dc.identifier.authorityMcMillan, AS=rp00014en_HK
dc.identifier.authorityWong, MCM=rp00024en_HK
dc.identifier.authorityLeung, WK=rp00019en_HK
dc.identifier.authorityMok, MY=rp00490en_HK
dc.identifier.authorityLau, CS=rp01348en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s10067-007-0723-xen_HK
dc.identifier.pmid17899308-
dc.identifier.scopuseid_2-s2.0-40949125731en_HK
dc.identifier.hkuros140990-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-40949125731&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume27en_HK
dc.identifier.issue4en_HK
dc.identifier.spage429en_HK
dc.identifier.epage436en_HK
dc.identifier.eissn1434-9949-
dc.identifier.isiWOS:000253974600003-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLeung, KCM=26221830300en_HK
dc.identifier.scopusauthoridMcMillan, AS=7102843317en_HK
dc.identifier.scopusauthoridWong, MCM=26029250900en_HK
dc.identifier.scopusauthoridLeung, WK=25224691800en_HK
dc.identifier.scopusauthoridMok, MY=7006024184en_HK
dc.identifier.scopusauthoridLau, CS=14035682100en_HK
dc.identifier.citeulike2751982-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats